513 related articles for article (PubMed ID: 19792994)
1. Tenofovir for the treatment of hepatitis B virus.
Jenh AM; Thio CL; Pham PA
Pharmacotherapy; 2009 Oct; 29(10):1212-27. PubMed ID: 19792994
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Jenh AM; Pham PA
Expert Rev Anti Infect Ther; 2010 Oct; 8(10):1079-92. PubMed ID: 20954872
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
[TBL] [Abstract][Full Text] [Related]
4. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
[TBL] [Abstract][Full Text] [Related]
5. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Ristig MB; Crippin J; Aberg JA; Powderly WG; Lisker-Melman M; Kessels L; Tebas P
J Infect Dis; 2002 Dec; 186(12):1844-7. PubMed ID: 12447773
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir therapy for lamivudine resistance following liver transplantation.
Neff GW; Nery J; Lau DT; O'Brien CB; Duncan R; Shire NJ; Ruiz P; Nery C; Montalbano M; Muslu H; Safdar K; Schiff ER; Tzakis AG; Madariaga JR
Ann Pharmacother; 2004 Dec; 38(12):1999-2004. PubMed ID: 15507498
[TBL] [Abstract][Full Text] [Related]
8. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
9. Reversibility of cirrhosis in HIV/HBV coinfection.
Mallet VO; Dhalluin-Venier V; Verkarre V; Correas JM; Chaix ML; Viard JP; Pol S
Antivir Ther; 2007; 12(2):279-83. PubMed ID: 17503671
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir disoproxil fumarate.
Gallant JE; Deresinski S
Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
[TBL] [Abstract][Full Text] [Related]
11. Adefovir dipivoxil: new preparation. A third-line option in chronic hepatitis B.
Prescrire Int; 2004 Feb; 13(69):4-7. PubMed ID: 15055205
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of chronic hepatitis B in HIV co-infected patients].
Massard J; Benhamou Y
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt 2):S20-4. PubMed ID: 18662606
[TBL] [Abstract][Full Text] [Related]
13. Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.
Rago A; Lichtner M; Mecarocci S; Marocco R; Cenfra N; Belvisi V; Del Borgo C; Cimino G; Mastroianni CM
Antivir Ther; 2010; 15(6):929-32. PubMed ID: 20834107
[TBL] [Abstract][Full Text] [Related]
14. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
15. Chronic hepatitis B: preventing, detecting, and managing viral resistance.
Keeffe EB; Dieterich DT; Pawlotsky JM; Benhamou Y
Clin Gastroenterol Hepatol; 2008 Mar; 6(3):268-74. PubMed ID: 18328434
[TBL] [Abstract][Full Text] [Related]
16. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.
Mauss S; Berger F; Filmann N; Hueppe D; Henke J; Hegener P; Athmann C; Schmutz G; Herrmann E
J Hepatol; 2011 Dec; 55(6):1235-40. PubMed ID: 21703180
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Amini-Bavil-Olyaee S; Sheldon J; Lutz T; Trautwein C; Tacke F
AIDS; 2009 Jan; 23(2):268-72. PubMed ID: 19098499
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Gutiérrez S; Guillemi S; Jahnke N; Montessori V; Harrigan PR; Montaner JS
Clin Infect Dis; 2008 Feb; 46(3):e28-30. PubMed ID: 18181733
[TBL] [Abstract][Full Text] [Related]
19. Therapy of chronic hepatitis B: trends and developments.
Delaney WE; Borroto-Esoda K
Curr Opin Pharmacol; 2008 Oct; 8(5):532-40. PubMed ID: 18835366
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of chronic hepatitis B. Tenofovir--first choice in current EASL guidelines].
MMW Fortschr Med; 2009 May; 151(22):38-9. PubMed ID: 19526965
[No Abstract] [Full Text] [Related]
[Next] [New Search]
